Literature DB >> 12967935

Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: studies using the ecdysone-inducible mammalian expression system.

J McDonald1, T A Barnes, H Okawa, J Williams, G Calo', D J Rowbotham, D G Lambert.   

Abstract

(1) Partial agonism is primarily dependent upon receptor density and coupling efficiency. As these parameters are tissue/model dependent, intrinsic activity in different tissues can vary. We have utilised the ecdysone-inducible expression system containing the human nociceptin/orphanin FQ (N/OFQ) peptide receptor (hNOP) expressed in Chinese hamster ovary cells (CHOINDhNOP) to examine the activity of a range of partial agonists in receptor binding, GTPgamma35S binding and inhibition of adenylyl cyclase studies. (2) Incubation of CHOINDhNOP cells with ponasterone A (PON) induced hNOP expression ([leucyl-3H]N/OFQ binding) of 24, 68, 191 and 1101 fmol mg-1 protein at 1, 2, 5 and 10 microm PON, respectively. At 191 fmol mg-1, protein hNOP pharmacology was identical to that reported for other traditional expression systems. (3) pEC50 values for GTPgamma35S binding ranged from 7.23 to 7.72 (2-10 microm PON) for the partial agonist [Phe1psi(CH2-NH)Gly2]N/OFQ(1-13)-NH2 ([F/G]N/OFQ(1-13)-NH2) and 8.12-8.60 (1-10 microm PON) for N/OFQ(1-13)-NH2 and Emax values (stimulation factor relative to basal) ranged from 1.51 to 3.21 (2-10 microm PON) for [F/G]N/OFQ(1-13)-NH2 and 1.28-6.95 (1-10 microm) for N/OFQ(1-13)-NH2. Intrinsic activity of [F/G]N/OFQ(1-13)-NH2 relative to N/OFQ(1-13)-NH2 was 0.3-0.5. [F/G]N/OFQ(1-13)-NH2 did not stimulate GTPgamma35S binding at 1 microm PON, but competitively antagonised the effects of N/OFQ(1-13)-NH2 with a pKB=7.62. (4) pEC50 values for cAMP inhibition ranged from 8.26 to 8.32 (2-10 microm PON) for [F/G]N/OFQ(1-13)-NH2 and 9.42-10.35 for N/OFQ(1-13)-NH2 and Emax values (% inhibition) ranged from 19.6 to 83.2 for [F/G]N/OFQ(1-13)-NH2 and 40.9-86.0 for N/OFQ(1-13)-NH2. The intrinsic activity of [F/G]N/OFQ(1-13)-NH2 relative to N/OFQ(1-13)-NH2 was 0.48-0.97. (5) In the same cellular environment with receptor density as the only variable, we show that the profile of [F/G]N/OFQ(1-13)-NH2 can be manipulated to encompass full and partial agonism along with antagonism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12967935      PMCID: PMC1573999          DOI: 10.1038/sj.bjp.0705401

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  52 in total

1.  A simple and sensitive saturation assay method for the measurement of adenosine 3':5'-cyclic monophosphate.

Authors:  B L Brown; J D Albano; R P Ekins; A M Sgherzi
Journal:  Biochem J       Date:  1971-02       Impact factor: 3.857

2.  In vitro characterization of Ac-RYYRWK-NH(2), Ac-RYYRIK-NH(2) and [Phe1Psi(CH(2)-NH)Gly2] nociceptin(1-13)NH(2) at rat native and recombinant ORL(1) receptors.

Authors:  S L Mason; M Ho; J Nicholson; A T McKnight
Journal:  Neuropeptides       Date:  2001 Oct-Dec       Impact factor: 3.286

3.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

4.  Effects of [(pF)Phe(4)]nociceptin/orphanin FQ-(1-13)NH(2) on GTPgamma(35)S binding and cAMP formation in Chinese hamster ovary cells expressing the human nociceptin/orphanin FQ receptor.

Authors:  John McDonald; Timothy A Barnes; Girolamo Calo; Remo Guerrini; David J Rowbotham; David G Lambert
Journal:  Eur J Pharmacol       Date:  2002-05-17       Impact factor: 4.432

5.  Modulation of voltage-gated calcium channels by orphanin FQ in freshly dissociated hippocampal neurons.

Authors:  F Knoflach; R K Reinscheid; O Civelli; J A Kemp
Journal:  J Neurosci       Date:  1996-11-01       Impact factor: 6.167

6.  Pharmacological characterisation of [(pX)Phe4]nociceptin(1-13)amide analogues. 1. In vitro studies.

Authors:  Raffaella Bigoni; Daniela Rizzi; Anna Rizzi; Valeria Camarda; Remo Guerrini; David G Lambert; Eiji Hashiba; Hartmut Berger; Severo Salvadori; Domenico Regoli; Girolamo Calo'
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2002-04-19       Impact factor: 3.000

Review 7.  The ORL1 receptor: molecular pharmacology and signalling mechanisms.

Authors:  David C New; Yung H Wong
Journal:  Neurosignals       Date:  2002 Jul-Aug

8.  Increase by the ORL1 receptor (opioid receptor-like1) ligand, nociceptin, of inwardly rectifying K conductance in dorsal raphe nucleus neurones.

Authors:  C W Vaughan; M J Christie
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

9.  Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor.

Authors:  J C Meunier; C Mollereau; L Toll; C Suaudeau; C Moisand; P Alvinerie; J L Butour; J C Guillemot; P Ferrara; B Monsarrat
Journal:  Nature       Date:  1995-10-12       Impact factor: 49.962

10.  Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor.

Authors:  R K Reinscheid; H P Nothacker; A Bourson; A Ardati; R A Henningsen; J R Bunzow; D K Grandy; H Langen; F J Monsma; O Civelli
Journal:  Science       Date:  1995-11-03       Impact factor: 47.728

View more
  29 in total

1.  In vitro siRNA-mediated knockdown of the UT receptor: implications of density on the efficacy of a range of UT ligands.

Authors:  Benjamin D Hunt; Leong L Ng; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-06       Impact factor: 3.000

2.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

3.  In vitro and in vivo characterization of the bifunctional μ and δ opioid receptor ligand UFP-505.

Authors:  N Dietis; H Niwa; R Tose; J McDonald; V Ruggieri; M Filaferro; G Vitale; L Micheli; C Ghelardini; S Salvadori; G Calo; R Guerrini; D J Rowbotham; D G Lambert
Journal:  Br J Pharmacol       Date:  2018-05-14       Impact factor: 8.739

4.  Pharmacological profile of the cyclic nociceptin/orphanin FQ analogues c[Cys10,14]N/OFQ(1-14)NH2 and c[Nphe1,Cys10,14]N/OFQ(1-14)NH2.

Authors:  M Kitayama; T A Barnes; G Carra; J McDonald; G Calo; R Guerrini; D J Rowbotham; G Smith; D G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-04       Impact factor: 3.000

Review 5.  Molecular and cellular analysis of human histamine receptor subtypes.

Authors:  Roland Seifert; Andrea Strasser; Erich H Schneider; Detlef Neumann; Stefan Dove; Armin Buschauer
Journal:  Trends Pharmacol Sci       Date:  2012-12-17       Impact factor: 14.819

Review 6.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

7.  Chronic high-NaCl intake prolongs the cardiorenal responses to central N/OFQ and produces regional changes in the endogenous brain NOP receptor system.

Authors:  Richard D Wainford; Daniel R Kapusta
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-11-05       Impact factor: 3.619

8.  Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein G alpha qi5.

Authors:  Valeria Camarda; Carmela Fischetti; Nicholas Anzellotti; Paola Molinari; Caterina Ambrosio; Evi Kostenis; Domenico Regoli; Claudio Trapella; Remo Guerrini; Salvadori Severo; Girolamo Calo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-01-28       Impact factor: 3.000

9.  Differential activation of the μ-opioid receptor by oxycodone and morphine in pain-related brain regions in a bone cancer pain model.

Authors:  Atsushi Nakamura; Minoru Hasegawa; Kazuhisa Minami; Tomoe Kanbara; Takako Tomii; Atsushi Nishiyori; Minoru Narita; Tsutomu Suzuki; Akira Kato
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

10.  Effects of receptor density on Nociceptin/OrphaninFQ peptide receptor desensitisation: studies using the ecdysone inducible expression system.

Authors:  T A Barnes; J McDonald; D J Rowbotham; T L Duarte; D G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-25       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.